|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
3
|
Resverlogix Corp.
|
Jan 09, 2019 01:07PM
|
|
Re: RVX buyout projection at $30 US minimum
|
1
|
Resverlogix Corp.
|
Nov 01, 2018 09:54PM
|
|
Re: Rules of thumb and broken thumbs...
|
9
|
Resverlogix Corp.
|
Sep 29, 2020 03:47PM
|
|
Re: Righting the (underpowered) vessel
|
7
|
Resverlogix Corp.
|
Oct 31, 2019 05:43PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
3
|
Resverlogix Corp.
|
Nov 02, 2020 10:15PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
8
|
Resverlogix Corp.
|
Nov 02, 2020 06:37PM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
4
|
Resverlogix Corp.
|
Sep 04, 2018 12:33PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
9
|
Resverlogix Corp.
|
Mar 26, 2020 01:10PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
8
|
Resverlogix Corp.
|
Mar 24, 2020 02:05PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
8
|
Resverlogix Corp.
|
Mar 26, 2020 02:36PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 24, 2020 03:54PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 24, 2020 04:20PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 26, 2020 02:55PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 24, 2020 04:33PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 05:00PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 06:50PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 07:01PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:17PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:30PM
|
|
Re: Resverlogix AGM webcast 9/12/2018
|
9
|
Resverlogix Corp.
|
Sep 10, 2018 10:17PM
|
